Green Cross Corp
KRX:006280
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
108 100
174 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Green Cross Corp
Green Cross Corp
Capital Expenditures
Green Cross Corp
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Green Cross Corp
KRX:006280
|
Capital Expenditures
-₩73.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-1%
|
|
|
Celltrion Inc
KRX:068270
|
Capital Expenditures
-₩350.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Capital Expenditures
-₩50.3B
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Capital Expenditures
-₩29.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Capital Expenditures
-₩27.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Capital Expenditures
-₩32.9B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
Green Cross Corp
Glance View
Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Yongin, Gyeonggi-Do. The firm mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The firm also provides genome analysis services.
See Also
What is Green Cross Corp's Capital Expenditures?
Capital Expenditures
-73.2B
KRW
Based on the financial report for Sep 30, 2024, Green Cross Corp's Capital Expenditures amounts to -73.2B KRW.
What is Green Cross Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-1%
Over the last year, the Capital Expenditures growth was 41%. The average annual Capital Expenditures growth rates for Green Cross Corp have been 12% over the past three years , 12% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
